| Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distorsion product otoacoustic emission K Biro, L Noszek, P Prekopp, K Nagyiványi, L Géczi, I Gaudi, I Bodrogi Oncology 70 (3), 177-184, 2006 | 77 | 2006 |
| Detection of early ototoxic effect in testicular-cancer patients treated with cisplatin by transiently evoked otoacoustic emission: a pilot study K Biro, M Baki, B Büki, L Noszek, L Jokuti Oncology 54 (5), 387-390, 1997 | 24 | 1997 |
| Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients K Biró Magyar Onkologia 53 (3), 279-283, 2009 | 19 | 2009 |
| Synergistic survival: a new phenomenon connected to adverse events of first-line sunitinib treatment in advanced renal cell carcinoma K Nagyiványi, B Budai, K Bíró, F Gyergyay, L Noszek, Z Küronya, ... Clinical Genitourinary Cancer 14 (4), 314-322, 2016 | 17 | 2016 |
| A case study on the potential angiogenic effect of human chorionic gonadotropin hormone in rapid progression and spontaneous regression of metastatic renal cell carcinoma … L Mangel, K Bíró, I Battyáni, P Göcze, T Tornóczky, E Kálmán BMC cancer 15, 1-7, 2015 | 13 | 2015 |
| Prevalence of APC and PTEN Alterations in Urachal Cancer N Nagy, H Reis, B Hadaschik, C Niedworok, O Módos, A Szendrői, K Bíró, ... Pathology & Oncology Research 26, 2773-2781, 2020 | 12 | 2020 |
| Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin‐based therapy L Noszek, B Budai, P Prekopp, R Széchenyi, M Szőnyi, S Talpai, ... The Laryngoscope 127 (8), E277-E282, 2017 | 12 | 2017 |
| GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs B Budai, P Prekopp, L Noszek, ER Kovács, M Szőnyi, DJ Erdélyi, K Bíró, ... Journal of Molecular Medicine 98, 963-971, 2020 | 11 | 2020 |
| Sunitinib rechallenge after other targeted therapies in metastatic renal cell carcinoma patients: a single-center, retrospective study K Nagyiványi, B Budai, F Gyergyay, Z Küronya, K Bíró, L Géczi Clinical Drug Investigation 39, 577-583, 2019 | 7 | 2019 |
| Treatment strategies for advanced prostate cancer Z Küronya, K Bíró, L Géczi, H Németh Magyar Onkologia 59 (3), 229-240, 2015 | 7 | 2015 |
| Sunitinib rechallange in metastatic renal cell carcinoma patients K Nagyivanyi, K Biro, F Gyergyay, Z Küronya, H Nemeth, L Géczi Annals of Oncology 23, ix281, 2012 | 7 | 2012 |
| Low socioeconomic position is a risk factor for delay to treatment and mortality of testicular cancer patients in Hungary, a prospective study Z Küronya, G Fröhlich, A Ladányi, T Martin, L Géczi, F Gyergyai, ... BMC Public Health 21, 1-11, 2021 | 6 | 2021 |
| Terápiás szekvenciák az előrehaladott/áttétes prosztatadaganatok gyógyszeres kezelésében A Maráz, L Géczi, K Bíró, L Varga, Z Küronya Magyar Onkológia 64, 263-272, 2020 | 6 | 2020 |
| ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer Z Küronya, F Sükösd, L Varga, K Bíró, F Gyergyay, L Géczi, K Nagyiványi, ... Urologic Oncology: Seminars and Original Investigations 37 (4), 289. e1-289. e9, 2019 | 6 | 2019 |
| A retrospective analysis of the first 41 mCRPC patients with bone pain treated with radium-223 at the national institute of oncology in hungary Z Küronya, I Sinkovics, P Ágoston, K Biró, I Bodrogi, I Böde, M Dank, ... Pathology & Oncology Research 23, 777-783, 2017 | 6 | 2017 |
| Histology, 12p status, and IMP3 expression separate subtypes in testicular teratomas D Semjén, K Bíró, E Kapitány, E Kálmán, T Tornóczky, B Kajtár Virchows Archiv 477, 103-110, 2020 | 5 | 2020 |
| Abiraterone acetate+ prednisolone treatment beyond prostate specific antigen and radiographic progression in metastatic castration-resistant prostate cancer patients K Biró, B Budai, M Szőnyi, Z Küronya, F Gyergyay, K Nagyiványi, L Géczi Urologic Oncology: Seminars and Original Investigations 36 (2), 81. e1-81. e7, 2018 | 5 | 2018 |
| Predictive markers of first line pazopanib treatment in kidney cancer Z Küronya, MD Szőnyi, K Nagyiványi, F Gyergyay, L Géczi, B Budai, ... Pathology & Oncology Research 26, 2475-2481, 2020 | 4 | 2020 |
| Neutrophil-to-lymphocyte ratio in primary mediastinal germ cell tumors: A retrospective analysis of> 20 years single institution experience L Géczi, B Budai, N Polk, F Fazekas, I Bodrogi, K Biró Current Problems in Cancer 44 (4), 100537, 2020 | 3 | 2020 |
| The role of exercise in prostate cancer prevention and treatment K Biró, L Géczi Magyar Onkologia 63 (1), 60-64, 2019 | 3 | 2019 |
Dániel János ErdélyiPediatrician, HematologistE-mail megerősítve itt: med.semmelweis-univ.hu
